Prevention strategies for congenital cytomegalovirus infection. Issue 5 (October 2021)

• Record Type: Journal Article
• Authors: Tol, Isabel; Heath, Paul T.; Khalil, Asma
• Is Part Of: Current opinion in infectious diseases. Volume 34:Issue 5(2021)
• Publication Date: 2021-10
• Subjects: congenital cytomegalovirus -- prevention -- valaciclovir; Communicable diseases -- Periodicals; Communicable Diseases -- Periodicals; Review Literature -- Periodicals; 616.905
• DOI: 10.1097/QCO.0000000000000777
• Languages: English
• ISSNs: 0951-7375

Abstract

Abstract : Purpose of review: Cytomegalovirus (CMV) is the most common viral cause of congenital infection, occurring in approximately 1–2% of live births worldwide. Given our increasing knowledge of risk, advances in the identification of maternal infection, and the extremely limited options for the treatment of fetal infection, the prevention is a promising direction for research efforts. Recently, there have been several exciting studies assessing different ways of preventing congenital infection in the fetus and one in particular has focused on the use of valaciclovir. Recent findings: A recent study reported a 71% reduction in vertical transmission of CMV with the use of oral valaciclovir following maternal primary CMV infection early in pregnancy. The clinical impact of this study could be enormous and it has particular implications for considerations around maternal serological screening in the first trimester of pregnancy. Further research assessing behaviour modifications during early pregnancy could also provide evidence for an effective primary prevention technique. Summary: Prevention of congenital CMV infection, whether primary, secondary or tertiary, is possible, however, there are barriers to its utilisation in a clinical setting. The main limitation is the requirement for early, effective and large-scale serological screening of mothers to detect asymptomatic primary infection.